Anzeige
Mehr »
Login
Mittwoch, 06.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLTL | ISIN: US86150R1077 | Ticker-Symbol: 0GT
Tradegate
05.11.24
21:40 Uhr
11,800 Euro
-0,200
-1,67 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
STOKE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
STOKE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
11,80012,10005.11.
11,80012,20005.11.

Aktuelle News zur STOKE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiStoke Therapeutics, Inc. - 10-Q, Quarterly Report-
DiStoke Therapeutics GAAP EPS of -$0.47 beats by $0.06, revenue of $4.89M beats by $1.29M1
DiStoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates29BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine...
► Artikel lesen
DiStoke Therapeutics, Inc. - 8-K, Current Report-
23.09.Skorpios Trust sells $27.2 million of Stoke Therapeutics stock1
11.09.Stoke Therapeutics-Aktie erhält Kaufempfehlung aufgrund vielversprechender Studiendaten2
11.09.Analyst bullish on Stoke Therapeutics stock following key epilepsy drug data8
11.09.Analyst optimistisch für Stoke Therapeutics-Aktie nach wichtigen Daten zu Epilepsie-Medikament-
10.09.Stoke Therapeutics settles director pay dispute2
10.09.Stoke Therapeutics, Inc. - 8-K, Current Report1
03.09.Stoke Therapeutics, Inc.: Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome309- First presentation of landmark data from Phase 1/2a and OLE studies of zorevunersen that showed substantial reductions in seizures and continued improvements in multiple measures of cognition...
► Artikel lesen
07.08.Stoke Therapeutics, Inc. - 10-Q, Quarterly Report1
07.08.Stoke Therapeutics GAAP EPS of -$0.46, revenue of $4.83M1
07.08.Stoke Therapeutics, Inc. - 8-K, Current Report1
07.08.Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates231BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine...
► Artikel lesen
28.06.A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics1
21.06.Stoke Therapeutics, Inc. - 8-K, Current Report1
06.06.Stoke Therapeutics, Inc. - 8-K, Current Report1
06.05.Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates138BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression...
► Artikel lesen
25.03.Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results114BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1